These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36335019)

  • 1. Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP/-DQ on engraftment in cord blood transplantation.
    Jo T; Arai Y; Hatanaka K; Ishii H; Ono A; Matsuyama N; Mori J; Koh Y; Azuma F; Kimura T
    Cytotherapy; 2023 Apr; 25(4):407-414. PubMed ID: 36335019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte Crossmatch Testing or Donor HLA-DP and -DQ Allele Typing Effectiveness in Single Cord Blood Transplantation for Patients With Anti-HLA Antibodies Other Than Against HLA-A, -B, -C, and -DRB1.
    Osada M; Yamamoto H; Watanabe O; Yamaguchi K; Kageyama K; Kaji D; Taya Y; Nishida A; Ishiwata K; Takagi S; Makino S; Asano-Mori Y; Yamamoto G; Taniguchi S; Wake A; Uchida N
    Transplant Cell Ther; 2024 Jul; 30(7):696.e1-696.e14. PubMed ID: 38641011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies.
    Yamamoto H; Uchida N; Matsuno N; Ota H; Kageyama K; Wada S; Kaji D; Nishida A; Ishiwata K; Takagi S; Tsuji M; Asano-Mori Y; Yamamoto G; Izutsu K; Masuoka K; Wake A; Yoneyama A; Makino S; Taniguchi S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1634-40. PubMed ID: 24972251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.
    Uchibori Y; Onodera K; Onishi Y; Komatsu H; Takenaka K; Narumi Y; Watanabe T; Nakamura H; Sakurai K; Hashimoto K; Inokura K; Ichikawa S; Fukuhara N; Yokoyama H; Harigae H
    Tohoku J Exp Med; 2023 Oct; 261(2):123-127. PubMed ID: 37558420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation.
    Zhang R; He Y; Yang D; Jiang E; Ma Q; Pang A; Zhai W; Wei J; Feng S; Han M
    J Clin Lab Anal; 2020 Jul; 34(7):e23261. PubMed ID: 32112480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodies.
    Dahi PB; Barone J; Devlin SM; Byam C; Lubin M; Ponce DM; Giralt S; Kernan NA; Scaradavou A; Hsu SH; Barker JN
    Biol Blood Marrow Transplant; 2014 May; 20(5):735-9. PubMed ID: 24462980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
    Cutler C; Kim HT; Sun L; Sese D; Glotzbecker B; Armand P; Koreth J; Ho V; Alyea E; Ballen K; Ritz J; Soiffer RJ; Milford E; Antin JH
    Blood; 2011 Dec; 118(25):6691-7. PubMed ID: 21940825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.
    Flomenberg N; Baxter-Lowe LA; Confer D; Fernandez-Vina M; Filipovich A; Horowitz M; Hurley C; Kollman C; Anasetti C; Noreen H; Begovich A; Hildebrand W; Petersdorf E; Schmeckpeper B; Setterholm M; Trachtenberg E; Williams T; Yunis E; Weisdorf D
    Blood; 2004 Oct; 104(7):1923-30. PubMed ID: 15191952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HLA antibodies in double umbilical cord blood transplantation.
    Brunstein CG; Noreen H; DeFor TE; Maurer D; Miller JS; Wagner JE
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1704-8. PubMed ID: 21601639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis.
    Ruggeri A; Rocha V; Masson E; Labopin M; Cunha R; Absi L; Boudifa A; Coeffic B; Devys A; De Matteis M; Dubois V; Hanau D; Hau F; Jollet I; Masson D; Pedron B; Perrier P; Picard C; Ramouneau-Pigot A; Volt F; Charron D; Gluckman E; Loiseau P
    Haematologica; 2013 Jul; 98(7):1154-60. PubMed ID: 23242594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor-Specific HLA Antibodies Are Associated with Graft Failure and Delayed Hematologic Recovery after Unrelated Donor Hematopoietic Cell Transplantation.
    Lima ACM; Getz J; do Amaral GB; Loth G; Funke VAM; Nabhan SK; Petterle RR; de Marco R; Gerbase-DeLima M; Pereira NF; Bonfim C; Pasquini R
    Transplant Cell Ther; 2023 Aug; 29(8):493.e1-493.e10. PubMed ID: 37220839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
    Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
    Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets.
    Chang YJ; Zhao XY; Xu LP; Zhang XH; Wang Y; Han W; Chen H; Wang FR; Mo XD; Zhang YY; Huo MR; Zhao XS; Y K; Liu KY; Huang XJ
    J Hematol Oncol; 2015 Jul; 8():84. PubMed ID: 26156584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience.
    Petersdorf EW; Kollman C; Hurley CK; Dupont B; Nademanee A; Begovich AB; Weisdorf D; McGlave P
    Blood; 2001 Nov; 98(10):2922-9. PubMed ID: 11698272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates.
    Cao LQ; Lv M; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ; Chang YJ
    Sci Rep; 2020 Feb; 10(1):2367. PubMed ID: 32047235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and impact of HLA and MICA allele mismatching on donor-specific antibodies induction in kidney transplant rejection.
    Romphruk AV; Simtong P; Suntornnipat J; Sudwilai Y; Cheunta S; Chan-On C; Leelayuwat C
    Nephrology (Carlton); 2021 Oct; 26(10):833-841. PubMed ID: 34197005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Untreated Donor-Specific HLA Antibodies Are Associated With Graft Failure and Poor Survival After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Pediatric Patients With Nonmalignant Disorders.
    Lima ACM; Bonfim C; Getz J; do Amaral GB; Petterle RR; Loth G; Nabhan SK; de Marco R; Gerbase-DeLima M; Pereira NF; Pasquini R
    Transplant Cell Ther; 2022 Oct; 28(10):698.e1-698.e11. PubMed ID: 35882362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant.
    Bailén R; Vicario JL; Solán L; Sánchez-Vadillo I; Herrera P; Calbacho M; Alenda R; López-Lorenzo JL; Humala K; Chinea A; Sánchez-Pina J; Balas A; Moreno MÁ; Arzuaga J; Pradillo V; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
    Front Immunol; 2021; 12():674658. PubMed ID: 34093576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.